MAPT and Alzheimer disease: Driscoll and colleagues found no association between serum sαKl and AD biomarkers (CSF Aβ42/40, Aβ42, T-tau, P-tau) in pre-symptomatic individuals.23 Conversely, Ren and colleagues reported a negative correlation between plasma sαKl and CSF Aβ42, but not T-tau or P-tau181.24 Grøndvedt and colleagues presented a more complex picture: CSF sαKl positively correlated with CSF Aβ42 and negatively with CSF T-tau and P-tau181, supporting a potential modulatory role in AD pathology.